In a recent study posted to the medRxiv preprint server, researchers assessed the impact of coronavirus disease 2019 (COVID-19) on the prescribing safety of high-risk medications on a national scale in England.
A recent study posted to the medRxiv preprint server investigated the association of renin-angiotensin-aldosterone system (RAAS)-mediated hypertension (HT) with coronavirus disease 2019 (COVID-19).
Almost half of the U.S. adult population has high blood pressure - or hypertension - and about 20% of these patients have treatment-resistant hypertension.